Kevin Tang Biography and Net Worth

Director of Aurinia Pharmaceuticals

Mr. Tang has served as Director, Chair and Chair of the Governance Committee since 2024. He is the President of Tang Capital Management, LLC, a life sciences-focused investment company he founded in 2002. Mr. Tang founded Concentra Biosciences, LLC in 2023 and has since served as its Chairman. From 2014 through its acquisition by Innoviva, Inc. in 2022, he served as Chairman of La Jolla Pharmaceutical Company. In 2013, Mr. Tang founded Odonate Therapeutics, Inc. and served as its Chairman and Chief Executive Officer through 2022. He co-founded Heron Therapeutics, Inc. in 2009 and served as Director from 2009 to 2012 and Chairman from 2012 to 2020. From 2009 through its acquisition by Endo, Inc. in 2010, Mr. Tang served as Director of Penwest Pharmaceuticals Co. In 2006, he co-founded Ardea Biosciences, Inc. and served as a Director through its acquisition by AstraZeneca PLC in 2012. From 2001 to 2008, Mr. Tang served as a Director of Trimeris, Inc. (now AstraZeneca PLC). From 1993 to 2001, he was a research analyst at Deutsche Banc Alex Brown, Inc., an investment banking firm, and most recently was a Managing Director and head of the firm’s Life Sciences research group. Mr. Tang received a B.S. degree from Duke University.

What is Kevin Tang's net worth?: The estimated net worth of Kevin Tang is at least $176.40 million as of August 4th, 2025. Tang owns 11,129,500 shares of Aurinia Pharmaceuticals stock worth more than $176,402,575 as of December 15th. This net worth estimate does not reflect any other investments that Tang may own. Learn More about Kevin Tang's net worth.
How do I contact Kevin Tang?: The corporate mailing address for Tang and other Aurinia Pharmaceuticals executives is 4464 MARKHAM STREET SUITE 1203, VICTORIA A1, V8Z 7X8. Aurinia Pharmaceuticals can also be reached via phone at 250-708-4272 and via email at [email protected]. Learn More on Kevin Tang's contact information.
Has Kevin Tang been buying or selling shares of Aurinia Pharmaceuticals?: Kevin Tang has not been actively trading shares of Aurinia Pharmaceuticals during the last ninety days. Most recently, on Tuesday, August 5th, Kevin Tang bought 200,000 shares of Aurinia Pharmaceuticals stock. The stock was acquired at an average cost of $11.68 per share, with a total value of $2,336,000.00. Following the completion of the transaction, the director now directly owns 11,329,500 shares of the company's stock, valued at $132,328,560. Learn More on Kevin Tang's trading history.
Who are Aurinia Pharmaceuticals' active insiders?: Aurinia Pharmaceuticals' insider roster includes Jeffrey Bailey (Director), Matthew Donley (VP), Peter Greenleaf (CEO), Scott Habig (Chief Commercial Officer), Joseph Hagan (Director), Robert Huizinga (EVP), David Jayne (Director), Greg Keenan (Chief Medical Officer), Jill Leversage (Director), Michael Martin (Insider), Joseph Miller (CFO), Neil Solomons (Insider), and Kevin Tang (Director). Learn More on Aurinia Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Aurinia Pharmaceuticals?: In the last twelve months, Aurinia Pharmaceuticals insiders bought shares 3 times. They purchased a total of 1,300,000 shares worth more than $13,590,000.00. In the last twelve months, insiders at the biotechnology company sold shares 5 times. They sold a total of 343,898 shares worth more than $2,753,094.15. The most recent insider tranaction occured on August, 5th when Director Kevin Tang bought 200,000 shares worth more than $2,336,000.00. Insiders at Aurinia Pharmaceuticals own 12.2% of the company. Learn More about insider trades at Aurinia Pharmaceuticals.
Information on this page was last updated on 8/5/2025.

Kevin Tang Insider Trading History at Aurinia Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/5/2025	Buy	200,000	$11.68	$2,336,000.00	11,329,500
8/4/2025	Buy	100,000	$11.34	$1,134,000.00	11,129,500
8/1/2025	Buy	1,000,000	$10.12	$10,120,000.00	11,029,500

Kevin Tang Buying and Selling Activity at Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Company Overview

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Today's Range

Now: $15.85

$15.71

$16.00

50 Day Range

MA: $13.95

$11.10

$16.37

2 Week Range

Now: $15.85

$6.55

$16.48

Volume

959,593 shs

Average Volume

1,556,055 shs

Market Capitalization

$2.09 billion

P/E Ratio

28.30

Dividend Yield

N/A

Beta

1.42